Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study

Abstract

Background While oral antidepressants reach efficacy after weeks, single-dose intravenous (i.v.) ketamine has rapid, yet time-limited antidepressant effects. We aimed to determine the efficacy and safety of single-dose i.v. ketamine augmentation of escitalopram in major depressive disorder (MDD). Method Thirty outpatients with severe MDD (17-item Hamilton Rating Scale for Depression total score ⩾ 24) were randomized to 4 weeks double-blind treatment with escitalopram 10 mg/day+single-dose i.v. ketamine (0.5 mg/kg over 40 min) or escitalopram 10 mg/day + placebo (0.9% i.v. saline). Depressive symptoms were measured using the Montgomery-Asberg Depression Rating Scale (MADRS) and the Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR). Suicidal ideation was evaluated with the QIDS-SR item 12. Adverse psychopathological effects were measured with the Brief Psychiatric Rating Scale (BPRS)-positive symptoms, Young Mania Rating Scale (YMRS) and Clinician Administered Dissociative States Scale (CADSS). Patients were assessed at baseline, 1, 2, 4, 24 and 72 h and 7, 14, 21 and 28 days. Time to response (⩾ 50% MADRS score reduction) was the primary outcome. Results By 4 weeks, more escitalopram + ketamine-treated than escitalopram + placebo-treated patients responded (92.3% v. 57.1%, p = 0.04) and remitted (76.9% v. 14.3%, p = 0.001), with significantly shorter time to response [hazard ratio (HR) 0.04, 95% confidence interval (CI) 0.01-0.22, p Conclusions Single-dose i…

Overview

Integrity signals

Registry

Crossref · 10.1017/s0033291715002159

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 45 references

Research works printed but not linked: 4

  1. 2003, Guideline for the Prevention and Treatment of Psychiatric Disorders in China
  2. Zhu, 1998, Manual of Rating Scales in Psychiatry, 121
  3. Zhang, 1983, The application of the Chinese version of the Brief Psychiatric Rating Scale (BPRS) (in Chinese), Chinese Journal of Nervous and Mental Diseases, 9, 76
  4. Xie, 1984, Use of the Chinese version of the Hamilton rating scale for depression in general population and patients with major depression (in Chinese), Chinese Journal of Nervous and Mental Diseases, 10, 346

Cited by

See all 148

Metadata

Authors
Hu, Y.-D., Xiang, Y.-T., Fang, J.-X., Zu, S., Sha, S., Shi, H., Ungvari, G. S., Correll, C. U., Chiu, H. F. K., Xue, Y., Tian, T.-F., Wu, A.-S., Ma, X., & Wang, G.
Affiliations
  • Capital Medical University (CN)
  • University of Macau (MO)
  • The University of Western Australia (AU)
  • Northwell Health (US)
  • Chinese University of Hong Kong (HK)
Corresponding author
  • Xiang, Y.-T.
  • Wang, G.
Venue
Psychological Medicine
Published
2015-10-19
Volume
46
Issue
3
Pages
623-635
ISSN
  • 0033-2917 (ISSN-L)
  • 1469-8978
OpenAlex
W1748696538
Cited by
146
References
45
Citations by year
2026: 7 · 2025: 9 · 2024: 15 · 2023: 12 · 2022: 17 · 2021: 19 · 2020: 19 · 2019: 14 · 2018: 15 · 2017: 14 · 2016: 5
FWCI
8.17
Type
journal article
Language
en
Open access
closed
Locations
  • Psychological Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
escitalopram, major depressive disorder, antidepressant augmentation, rapid antidepressant response, remission, suicidal ideation, mania, treatment safety, outpatients, severe depression, time to response, time to remission, antidepressant efficacy
MeSH terms
Adolescent, Adult, Antidepressive Agents, China, Major Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Female, Humans, Ketamine, Male, Middle Aged, Outpatients, Personality Inventory, Psychiatric Status Rating Scales, Severity of Illness Index, Citalopram, Proportional Hazards Models, Treatment Outcome, Kaplan-Meier Estimate, Young Adult, Self Report, Administration, Intravenous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. https://app.cochat.ai/papers/10.1017/s0033291715002159
The paper
Hu, Y.-D., Xiang, Y.-T., Fang, J.-X., Zu, S., Sha, S., Shi, H., Ungvari, G. S., Correll, C. U., Chiu, H. F. K., Xue, Y., Tian, T.-F., Wu, A.-S., Ma, X., & Wang, G. (2016). Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychological Medicine. https://doi.org/10.1017/s0033291715002159

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.